Advertisement News Archives - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

News

January 27, 2022

Roche gets FDA priority review for Evrysdi to treat SMA in new-borns

Swiss healthcare company Roche has received the US Food and Drug Administration (FDA) priority review for its Evrysdi (risdiplam) to treat spinal muscular atrophy (SMA) in new-borns.

Roche gets FDA priority review for Evrysdi to treat SMA in new-borns